For example, it was reported that enhanced tumor regression occurred when PD-1 blockade was incorporated into an oncolytic VV platform, while other studies have shown that systemic administration of ICIs in combination with OVVs can synergistically increase CD8+ T cell infiltration and reduce tumor burden. Here, PDCD1 is linked to neoplasm.